NCT05373433View on ClinicalTrials.gov

To Evaluate SSD8432/Ritonavir in Adults With COVID-19

PHASE2/PHASE3UnknownINTERVENTIONAL
Enrollment

670

Participants

Timeline

Start Date

May 26, 2022

Primary Completion Date

May 31, 2023

Study Completion Date

October 31, 2023

Conditions
COVID-19
Interventions
DRUG

SSD8432 750mg

Experimental group:SSD8432 750mg and Ritonavir 100mg, Day1--Day5,BID

DRUG

SSD8432 placebo

Control group :SSD8432 placebo and Ritonavir placebo, Day1--Day5,BID

Sponsors
All Listed Sponsors
lead

Jiangsu Simcere Pharmaceutical Co., Ltd.

INDUSTRY

NCT05373433 - To Evaluate SSD8432/Ritonavir in Adults With COVID-19 | Biotech Hunter | Biotech Hunter